| Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide K Brendel, E Comets, C Laffont, C Laveille, F Mentré Pharmaceutical research 23, 2036-2049, 2006 | 378 | 2006 |
| Similarity of bisphenol A pharmacokinetics in rhesus monkeys and mice: relevance for human exposure JA Taylor, FS Vom Saal, WV Welshons, B Drury, G Rottinghaus, PA Hunt, ... Environmental health perspectives 119 (4), 422-430, 2011 | 327 | 2011 |
| Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial BR Haight, SM Learned, CM Laffont, PJ Fudala, Y Zhao, AS Garofalo, ... The Lancet 393 (10173), 778-790, 2019 | 241 | 2019 |
| Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004 K Brendel, C Dartois, E Comets, A Lemenuel-Diot, C Laveille, ... Clinical pharmacokinetics 46, 221-234, 2007 | 215 | 2007 |
| Intestinal secretion is a major route for parent ivermectin elimination in the rat CM Laffont, PL Toutain, M Alvinerie, A Bousquet-Mélou Drug metabolism and disposition 30 (6), 626-630, 2002 | 133 | 2002 |
| Licking behaviour and environmental contamination arising from pour-on ivermectin for cattle CM Laffont, M Alvinerie, A Bousquet-Mélou, PL Toutain International Journal for Parasitology 31 (14), 1687-1692, 2001 | 128 | 2001 |
| Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey C Dartois, K Brendel, E Comets, CM Laffont, C Laveille, B Tranchand, ... British journal of clinical pharmacology 64 (5), 603-612, 2007 | 110 | 2007 |
| Evaluation of different tests based on observations for external model evaluation of population analyses K Brendel, E Comets, C Laffont, F Mentré Journal of pharmacokinetics and pharmacodynamics 37, 49-65, 2010 | 106 | 2010 |
| Gentamicin Nephrotoxicity – A Comparison of In Vitro Findings with In VivoExperiments in Equines MR Van der Harst, S Bull, CM Laffont, WR Klein Veterinary research communications 29, 247-261, 2005 | 71 | 2005 |
| Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic–pharmacodynamic analysis and Monte Carlo simulations D Khachman, JM Conil, B Georges, S Saivin, G Houin, PL Toutain, ... Journal of antimicrobial chemotherapy 66 (8), 1798-1809, 2011 | 69 | 2011 |
| A pharmacokinetic model to document the actual disposition of topical ivermectin in cattle CM Laffont, A Bousquet‐mélou, D Bralet, M Alvinerie, J Fink-Gremmels, ... Veterinary research 34 (4), 445-460, 2003 | 64 | 2003 |
| Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure A Schmitt, L Gladieff, CM Laffont, A Evrard, JC Boyer, A Lansiaux, ... Journal of clinical oncology 28 (30), 4568-4574, 2010 | 63 | 2010 |
| Population pharmacokinetic modeling after repeated administrations of RBP‐6000, a new, subcutaneously injectable, long‐acting, sustained‐release formulation of buprenorphine … CM Laffont, R Gomeni, C Heidbreder, JP Jones Iii, AF Nasser The Journal of Clinical Pharmacology 56 (7), 806-815, 2016 | 58 | 2016 |
| RB-US-13-0001 Study Investigators.(2019). Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind … BR Haight, SM Learned, CM Laffont, PJ Fudala, Y Zhao, AS Garofalo, ... Lancet 393 (10173), 778-790, 0 | 51 | |
| A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection MW Sadiq, EI Nielsen, D Khachman, JM Conil, B Georges, G Houin, ... Journal of pharmacokinetics and pharmacodynamics 44, 69-79, 2017 | 48 | 2017 |
| Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of … CM Laffont, R Gomeni, B Zheng, C Heidbreder, PJ Fudala, AF Nasser Clinical pharmacokinetics 53, 533-543, 2014 | 47 | 2014 |
| Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm J Bertrand, E Comets, CM Laffont, M Chenel, F Mentré Journal of pharmacokinetics and pharmacodynamics 36, 317-339, 2009 | 47 | 2009 |
| Use of Monte Carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs JF Rey, CM Laffont, S Croubels, P De Backer, C Zemirline, E Bousquet, ... American Journal of Veterinary Research 75 (2), 124-131, 2014 | 38 | 2014 |
| Tolerance to opioid‐induced respiratory depression in chronic high‐dose opioid users: a model‐based comparison with opioid‐naive individuals MH Algera, E Olofsen, L Moss, RL Dobbins, M Niesters, M van Velzen, ... Clinical Pharmacology & Therapeutics 109 (3), 637-645, 2021 | 37 | 2021 |
| Population pharmacokinetic modeling and simulation to guide dose selection for RBP‐7000, a new sustained‐release formulation of risperidone CM Laffont, R Gomeni, B Zheng, C Heidbreder, PJ Fudala, AF Nasser The Journal of Clinical Pharmacology 55 (1), 93-103, 2015 | 36 | 2015 |
